Elicio Therapeutics, Inc. Common Stock
ELTXElicio Therapeutics, Inc. is a biotechnology company focused on developing immunotherapies that stimulate the body’s immune system to fight cancer. Their platform utilizes particulate vaccines designed to target and activate immune cells, aiming to improve the effectiveness of cancer treatments and address unmet medical needs in oncology.
Company News
Elicio Therapeutics (Nasdaq: ELTX), a clinical-stage biotech company, announced a registered direct offering of 4.38 million shares expected to raise approximately $15 million gross proceeds. The company plans to use the funds to support Phase 1 clinical development of ELI-002 7P in metastatic pancreatic cancer, pipeline advancement, and general ...
Elicio Therapeutics (ELTX), a clinical-stage biotech company developing immunotherapies for KRAS-driven cancers, was added to the Russell 2000 and Russell 3000 indexes as of June 26, 2026. The company is advancing its lead candidate ELI-002 7P, an off-the-shelf cancer immunotherapy targeting common KRAS mutations. However, the Phase 2 AMPLIFY-7P ...
Elicio Therapeutics announced that its Phase 2 AMPLIFY-7P study of ELI-002 7P did not meet the primary disease-free survival endpoint in the intent-to-treat population for adjuvant pancreatic cancer. However, post-hoc analyses showed promising results in the R0 resected patient subgroup (84% of enrolled patients) with a hazard ratio of 0.65 (p=0....
Elicio Therapeutics granted 30,300 inducement stock options to a new employee on February 17, 2026, at an exercise price of $8.59 per share. The options vest over four years with 25% vesting on the first anniversary and the remainder vesting monthly thereafter, subject to continued employment.
Elicio Therapeutics granted 22,400 inducement stock options to two new employees on January 15, 2026, at an exercise price of $7.81 per share. The options vest over four years with 25% vesting on the first anniversary and the remainder vesting ratably monthly thereafter.
